このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

EGFRミュート化された局所進行または転移性非小細胞肺癌の患者における第一選択治療としてのオシメルチニブとオシメルチニブとの組み合わせのBL-B01D1の研究

2026年11月15日 更新者:Sichuan Baili Pharmaceutical Co., Ltd.

EGFRが局所的に進行したまたは転移性非小細胞肺癌を患っている患者の第一選択治療としてのオシメルチニブとオシメルチニブとの組み合わせにおけるBL-B01D1の第III相ランダム化研究

This trial is a registered phase III, randomized, open-label, multicenter study to evaluate the efficacy and safety of BL-B01D1 in combination with osimertinib versus osimertinib as first-Line treatment in patients with EGFR-mutated locally advanced or metastatic Non-small Cell Lung Cancer.

調査の概要

状態

積極的、募集していない

研究の種類

介入

入学 (実際)

724

段階

  • フェーズ 3

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究場所

    • Shanghai Municipality
      • Shanghai、Shanghai Municipality、中国
        • Shanghai East Hospital

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

18年歳以上 (大人、高齢者)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

全て

説明

Inclusion Criteria:

  1. Sign the informed consent form voluntarily and follow the protocol requirements;
  2. Age ≥18 years old;
  3. Expected survival time ≥3 months;
  4. Patients with unresectable or radical radiotherapy for locally advanced non-small cell lung cancer;
  5. Documentation of EGFR sensitive mutations detected from tumor tissue or blood samples;
  6. Consent to provide archived tumor tissue samples or fresh tissue samples of primary or metastatic lesions at or after diagnosis for testing, including EGFR mutation type;
  7. At least one measurable lesion meeting the RECIST v1.1 definition was required;
  8. ECOG 0 or 1;
  9. The toxicity of previous antineoplastic therapy has returned to ≤ grade 1 as defined by NCI-CTCAE v5.0;
  10. No severe cardiac dysfunction, left ventricular ejection fraction ≥50%;
  11. The organ function level must meet the requirements on the premise that blood transfusion and colony-stimulating factor are not allowed within 14 days before the screening period;
  12. Urinary protein ≤2+ or < 1000mg/24h;
  13. For premenopausal women of childbearing potential, a pregnancy test must be performed within 7 days before the initiation of treatment, serum pregnancy must be negative, and the patient must not be lactating; All enrolled patients (male or female) were advised to use adequate barrier contraception throughout the treatment cycle and for 6 months after the end of treatment.

Exclusion Criteria:

  1. Previous histologic or cytological evidence of small cell or mixed small/non-small cell components;
  2. Patients with previous systemic therapy;
  3. Patients had received EGFR-TKI therapy;
  4. Studies received radical radiotherapy, major surgery, and large area radiotherapy within 4 weeks before randomization;
  5. History of severe heart disease and cerebrovascular disease;
  6. Unstable thrombotic events requiring therapeutic intervention within 6 months before screening; Infusion-related thrombosis was excluded;
  7. QT prolongation, complete left bundle branch block, III degree atrioventricular block, frequent and uncontrollable arrhythmia;
  8. Were diagnosed with active malignancy within 3 years before randomization;
  9. Hypertension poorly controlled by two antihypertensive drugs (systolic blood pressure &gt; 150 mmHg or diastolic blood pressure &gt; 100 mmHg);
  10. Patients with poor glycemic control;
  11. A history of ILD requiring steroid therapy, or current ILD or grade ≥2 radiation pneumonitis, or a suspicion of such disease;
  12. Complicated with pulmonary diseases leading to clinically severe respiratory function impairment;
  13. Patients with active central nervous system metastasis;
  14. Had a severe infection within 4 weeks before randomization;
  15. Patients with massive or symptomatic effusions or poorly controlled effusions;
  16. Imaging examination showed that the tumor had invaded or enveloped the large blood vessels in the abdomen, chest, neck, and pharynx;
  17. Serious unhealed wound, ulcer, or fracture within 4 weeks before signing the informed consent;
  18. Subjects with clinically significant bleeding or obvious bleeding tendency within 4 weeks before signing the informed consent;
  19. Patients with a history of inflammatory bowel disease, extensive bowel resection, immune enteritis, intestinal obstruction or chronic diarrhea;
  20. Patients with a history of allergy to recombinant humanized antibodies or to any of the excipients of BL-B01D1;
  21. Had autologous or allogeneic stem cell transplantation history;
  22. Human immunodeficiency virus antibody positive, active hepatitis B virus infection or hepatitis C virus infection;
  23. A history of severe neurological or psychiatric illness;
  24. Received other unmarketed investigational drugs or treatments within 4 weeks before randomization;
  25. Subjects scheduled for vaccination or who received live vaccine within 28 days before study randomization;
  26. Other circumstances in which the investigator considered it inappropriate to participate in the trial because of complications or other circumstances.

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:処理
  • 割り当て:ランダム化
  • 介入モデル:並列代入
  • マスキング:なし(オープンラベル)

武器と介入

参加者グループ / アーム
介入・治療
実験的:BL-B01D1 in Combination with Osimertinib

Participants receive BL-B01D1 in Combination with Osimertinib for the first cycle (3 weeks). Participants with clinical benefit could receive additional treatment for more cycles. The administration will be terminated because of disease progression or intolerable toxicity occurring or other reasons.

Administration by intravenous infusion for a cycle of 3 weeks.

他の名前:
  • BMS-986507
  • Iza-Bren
  • Izalontamab Brengitecan

Oral administration, 80mg daily for a cycle of 3 weeks.

アクティブコンパレータ:Osimertinib

Participants receive Osimertinib for the first cycle (3 weeks). Participants with clinical benefit could receive additional treatment for more cycles. The administration will be terminated because of disease progression or intolerable toxicity occurring or other reasons.

Oral administration, 80mg daily for a cycle of 3 weeks.

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Progression-free survival (PFS)
時間枠:Up to approximately 36 months

Progression-free survival (PFS) as assessed by BIRC is defined as the time between the date subjects are randomized and the first observation of disease progression (based on BICR's image-based assessment) or death.

Up to approximately 36 months

二次結果の測定

結果測定
メジャーの説明
時間枠
Overall survival (OS)
時間枠:Up to approximately 36 months

Overall survival (OS) is defined as the time between the subject's randomization date and subject's death.

Up to approximately 36 months
Objective Response Rate (ORR)
時間枠:Up to approximately 36 months

Objective response rate (ORR) is defined as the number of CR and PR in the treatment and control groups divided by the number of that group in the full analysis set (FAS).

Up to approximately 36 months
Disease Control Rate (DCR)
時間枠:Up to approximately 36 months

Disease Control Rate (DCR) : Percentage of all randomized subjects who rated the best overall response (BOR) as complete response (CR), partial response (PR), and disease stabilization (SD) according to RECIST 1.1 criteria.

Up to approximately 36 months
Duration of Response (DOR)
時間枠:Up to approximately 36 months

Duration of Response (DOR) : defined as the period from the date when tumor response is first recorded to the date when objective tumor progression is first recorded or the date of death.

Up to approximately 36 months
Treatment Emergent Adverse Event (TEAE)
時間枠:Up to approximately 36 months

TEAE is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally emerging, or any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a pre-existing condition during the treatment of BL-B01D1. The type, frequency and severity of TEAE will be evaluated during the treatment of BL-B01D1.

Up to approximately 36 months
Anti-drug antibody (ADA)
時間枠:Up to approximately 36 months

Frequency of anti-BL-B01D1 antibody (ADA) will be investigated.

Up to approximately 36 months

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2025年2月24日

一次修了 (推定)

2028年12月1日

研究の完了 (推定)

2028年12月1日

試験登録日

最初に提出

2025年2月16日

QC基準を満たした最初の提出物

2025年2月16日

最初の投稿 (実際)

2025年2月20日

学習記録の更新

投稿された最後の更新 (実際)

2026年11月17日

QC基準を満たした最後の更新が送信されました

2026年11月15日

最終確認日

2026年11月1日

詳しくは

本研究に関する用語

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

いいえ

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する